On Monday, Dunkin Brands Group Inc (NASDAQ:DNKN)’s shares inclined 2.39% to $55.18.
Baskin-Robbins, the world’s largest chain of ice cream specialty shops, is keeping guests cool this summer with its August Flavor of the Month, OREO® Malt Madness. This new flavor is a delicious combination of traditional chocolate malt-flavored ice cream, loaded with OREO® cookie pieces and a chocolate sea salt cookie flavored ribbon. OREO® Malt Madness can be enjoyed in a cup, cone or as a milkshake. To make things even sweeter this month, guests can upgrade any double scoop purchase with a freshly-baked waffle cone for no extra charge.
Baskin-Robbins is also ongoing its 70th birthday celebration this month with its special “Celebrate 31” promotion and on Monday, August 31st guests can enjoy any scoop of ice cream for $1.31 per scoop. The offer is valid for all 31 ice cream flavors, counting August’s Flavor of the Month, at participating Baskin-Robbins locations nationwide.*
Dunkin Brands Group, Inc., together with its auxiliaries, develops, franchises, and licenses quick service restaurants under the Dunkin Donuts and Baskin-Robbins brands worldwide. The company operates through four segments: Dunkin’ Donuts U.S., Dunkin’ Donuts International, Baskin-Robbins U.S., and Baskin-Robbins International. I
Arrowhead Research Corp (NASDAQ:ARWR)’s shares dropped -2.27% to $6.04.
Arrowhead Research Corporation (ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, recently declared that it will report its financial results for the fiscal 2015 third quarter ended June 30, 2015, on Tuesday, August 4, 2015, at 4:30 p.m. EDT. Investors may access a live audio webcast on the Company’s website at http://ir.arrowheadresearch.com/events.cfm. For analysts that wish to take part in the conference call, please dial 315-625-6887 and enter Conference ID 97375077.
Arrowhead Research Corporation develops novel drugs to treat intractable diseases in the United States. The company’s principal product candidates comprise ARC-520, an RNAi-based therapeutic that is in Phase IIa clinical trial to treat chronic hepatitis B virus infection; and ARC-AAT, a novel unlocked nucleobase analog containing RNAi-based therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. Its platform technology comprise Dynamic Polyconjugate platform, an RNAi delivery system that addresses multiple organ systems and cell types. T
At the end of Monday s trade, Abraxas Petroleum Corp. (NASDAQ:AXAS)‘s shares dipped -2.13% to $1.84.
Abraxas Petroleum Corporation (AXAS) offered the following operations update.
Williston Basin
At Abraxas’ North Fork prospect, in McKenzie County, North Dakota, the Jore 5H, Jore 6H, Jore 7H and Jore 8H, producing from the Middle Bakken, averaged 819 boepd (653 barrels of oil per day, 994 mcf of natural gas per day) (1) over the wells’ peak 30 days of production. Each well was constrained on a smaller than normal choke to minimize flaring. To date, total drill and complete costs (before any needed expenditures for pump) averaged $6.3 million. On the Ravin Northwest pad, the Ravin 8H, Sten–Rav 1H and Stenehjem 5H are planned to be accomplished in August. Recently, Abraxas successfully mobilized to the Stenehjem 10H-15H pad where it is presently drilling the intermediate section on the first well of a six well pad. Abraxas owns a working interest of about 76%, 74% and 78% in the Jore 5H-8H, Ravin Northwest wells and Stenehjem 10H-15H, respectively.
Abraxas Petroleum Corporation, an independent energy company, engages in the acquisition, exploitation, development, and production of oil and gas properties in the United States. The company operates oil and gas assets in the Rocky Mountain, Permian Basin, and onshore Gulf Coast regions.
OraSure Technologies, Inc. (NASDAQ:OSUR), ended its Monday’s trading session with 0.40% gain, and closed at $4.96.
OraSure Technologies, Inc. (OSUR), a leader in point of care diagnostic tests and specimen collection devices, recently declared that Douglas A. Michels, President and CEO, will speak to the investment community at the Canaccord Genuity 35th Annual Growth Conference in Boston, Massachusetts. The conference will be simultaneously webcast over the Internet.
Mr. Michels is planned to speak August 12, 2015, at about 2:00 PM Eastern Time (11:00 AM Pacific Time). Interested investors can access the live webcast of the presentation by going to OraSure Technologies’ web site, www.orasure.com, and clicking on the Investor Info link.
OraSure Technologies, Inc., together with its auxiliaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests that are used on other specimen types.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
